Goldman Sachs
COLL icon

Goldman Sachs’s Collegium Pharmaceutical COLL Stock Holding History

Goldman Sachs’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,000
Closed -$262K – 6378
2017
Q3 		$262K Hold
25,000
– – ﹤0.01% 5575
2017
Q2 		$313K Hold
25,000
– – ﹤0.01% 5473
2017
Q1 		$252K Buy
+25,000
New +$372K ﹤0.01% 5578

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Goldman Sachs's COLL Position: Q2 2026 in Review

Goldman Sachs reduced its Collegium Pharmaceutical (COLL) stake by 3.2% in Q2 2026, selling an estimated $622K and leaving 556,927 shares worth $20.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Goldman Sachs first reported a position in COLL in Q2 2015 and has held it in 44 quarters since. The position peaked at $30M in Q4 2025. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Goldman Sachs held 556,927 shares of Collegium Pharmaceutical worth $20.2M as of Q2 2026.
  • Goldman Sachs sold 18,214 Collegium Pharmaceutical shares in Q2 2026, an estimated $622K.
  • Collegium Pharmaceutical made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2614 holding.
  • Goldman Sachs first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 44 quarters since.
  • Goldman Sachs's Collegium Pharmaceutical position peaked at $30M in Q4 2025.
  • 280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.